Boc-L-天冬氨酸 4-甲酯 | 59768-74-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天冬氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Boc-L-天冬氨酸 4-甲酯
• 中文别名: Boc-L-天冬氨酸-4-甲酯；L-天冬氨酸Β甲脂；4-甲酯；Boc-L-天冬氨酸4-甲酯；BOC-L-天冬氨酸-5-甲酯；BOC-L-天冬氨酸甲酯；叔丁氧羰基-L-天冬氨酸4-甲酯；叔丁氧羰基-L-天冬氨酸 4-甲酯；Boc-Asp(OMe)-OH
• 英文名称: (S)-2-t-butoxycarbonylaminosuccinic acid 4-methyl ester
• 英文别名: (S)-2-((tert-butoxycarbonyl)amino)-4-methoxy-4-oxobutanoic acid；Boc-Asp(OMe)-OH；(2S)-2-[(tert-butoxycarbonyl)amino]-4-methoxy-4-oxobutanoic acid；N-Boc-L-aspartic acid 4-methyl ester；Boc-L-Asp(OMe)-OH；N-Boc aspartic acid β-methyl ester；Boc-L-aspartic acid 4-methyl ester；Boc-asp(OMe)；(2S)-4-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid
• CAS: 59768-74-0
• 化学式: C₁₀H₁₇NO₆
• 分子量: 247.248
• InChiKey: WFPSMPYVXFVVFA-LURJTMIESA-N

物化性质

• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• WGK Germany：
  3
• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存于阴凉干燥处，并密封在－20 ºC的环境中。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Boc-Asp(OMe)-OH
CAS-No. : 59768-74-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : Boc-L-aspartic acid 4-methyl ester
Formula : C10H17NO6
Molecular Weight : 247,25 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: crystalline
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 71 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

Boc-Asp(OMe)-OH是一种天冬氨酸衍生物。

反应信息

• 作为反应物：
  描述：

  Boc-L-天冬氨酸 4-甲酯 在 N-甲基吗啉 、 三氟化硼乙醚 、 氯甲酸乙酯 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 反应 7.0h， 生成 4-(2-羟基乙基)-2,2-二甲基噁唑啉-3-羧酸-(S)-叔丁酯
  参考文献：
  名称：

  NOVEL QUINOLINE -SUBSTITUTED COMPOUND

  摘要：

  本发明的目标是提供一种具有EGFR抑制作用和细胞生长抑制作用的新化合物，以及一种基于EGFR抑制作用的用于预防和/或治疗癌症的药物。本发明提供以下式（I）所代表的化合物或其盐。

  公开号：

  US20160194332A1
• 作为产物：
  描述：

  BOC-L-天冬氨酸二甲酯 在 lithium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 以41.2 g的产率得到Boc-L-天冬氨酸 4-甲酯
  参考文献：
  名称：

  通过天冬氨酸等价物的格氏反应合成手性 β-氨基酸衍生物

  摘要：

  通过 2,4,5-三氟苯基溴化镁与 L-天冬氨酸的 Weinreb 酰胺衍生物的格利雅反应，开发了一种手性 β-氨基酸衍生物的新合成路线。天冬氨酸等价物由L-天冬氨酸分四步合成，格氏试剂通过Br-Mg-交换反应制备。在格氏反应和随后的还原之后获得目标化合物。L-天冬氨酸很好地保留了手性胺的立体结构。

  DOI：

  10.3184/030823410x12843925746143
• 作为试剂：
  描述：

  C,C-di-pyridin-3-yl-methylamine 在 双氧水 、 Boc-L-天冬氨酸 4-甲酯 、 三乙胺 、 N,N'-二异丙基碳二亚胺 作用下， 以 氘代氯仿 、 二氯甲烷 、 水 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  催化对映选择性吡啶 N-氧化

  摘要：

  描述了取代吡啶的催化、对映选择性 N-氧化反应。该方法基于生物分子启发的催化循环，其中当天冬氨酰侧链在游离酸和过酸形式之间穿梭时，含天冬氨酸的肽提供高水平的不对称诱导。证明了带有被能够与催化剂形成氢键的基团取代的远程前立体中心的双(吡啶)底物的去对称化。我们的方法为富含杂环的分子环境中的手性吡啶框架提供了新的途径。对映体富集的吡啶 N-氧化物的代表性官能化进一步证明了该方法的实用性。两种古老的类药物支架（氯雷他定和伐尼克兰）中的不对称 N-氧化证明表明该方法在高度可变和独特的手性环境中可能具有普遍性，同时也揭示了该方法适用于吡啶和 1, 4-吡嗪类。

  DOI：

  10.1021/jacs.9b10414

文献信息

• Discovery of Dipeptide-Derived Catalysts for the Enantioselective Addition of Dimethylzinc to Aldehydes
  作者：Seock Yong Kang、Yong Sun Park

  DOI：10.1002/ejoc.201200063

  日期：2012.3

  new class of modular chiral catalysts derived from various amino acid-L-Pro dipeptides was prepared, and the catalysts were tested for their ability to catalyze the enantioselective addition of dimethylzinc to aromatic aldehydes. Dipeptides derived from L-Asp-L-Pro were identified as effective catalysts for the addition at room temperature with up to 97:3 er and 95 % yield.

  制备了一类新的模块化手性催化剂，这些催化剂来源于各种氨基酸-L-Pro 二肽，并测试了催化剂催化二甲基锌对芳香醛的对映选择性加成的能力。源自 L-Asp-L-Pro 的二肽被确定为在室温下添加的有效催化剂，效率高达 97:3，产率为 95%。
• Continuous-flow processes for the <i>S</i>-alkynylation of cysteine-containing peptides and thioglycosides under catalyst-free, oxidant-free and mild conditions
  作者：Long-Zhou Qin、Xin Yuan、Jie Liu、Meng-Yu Wu、Qi Sun、Xiu Duan、Xin-Peng Zhang、Jiang-Kai Qiu、Kai Guo

  DOI：10.1039/d1gc01937f

  日期：——

  Selective S-alkynylation of cysteine-containing peptides and 1-thioglycoside residues was developed using continuous flow.

  含半胱氨酸肽和1-硫代糖苷残基的选择性S-炔基化反应已经在连续流条件下开发。
• [EN] ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS<br/>[FR] COMPOSÉS DEPSIPEPTIDIQUES ANTHELMINTHIQUES
  申请人：MERIAL INC

  公开号：WO2018093920A1

  公开（公告）日：2018-05-24

  The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

  本发明提供了公式（I）的环状脱氨肽化合物，其中至少一个碳原子的立体化学构型与自然存在的环状脱氨肽PF1022A的基团Cy1、Cy2、R1、R2、R3、R4、Ra和Rb相比发生了倒置。该发明还提供了包含这些化合物的组合物，对危害动物的寄生虫具有有效性。这些化合物和组合物可用于对抗哺乳动物和鸟类体内或体表的寄生虫。该发明还提供了一种改进的方法，用于根除、控制和预防鸟类和哺乳动物的寄生虫感染。
• [EN] DUAL-ACTING ANTIHYPERTENSIVE AGENTS<br/>[FR] AGENTS ANTIHYPERTENSIFS À DOUBLE ACTION
  申请人：THERAVANCE INC

  公开号：WO2009035543A1

  公开（公告）日：2009-03-19

  The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下公式的化合物：(I) 其中：Ar、r、R3、Z、X和R5-7按说明书定义，或其药用可接受盐。这些化合物具有AT1受体拮抗活性和中性内肽酶抑制活性。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099274A1

  公开（公告）日：2003-12-04

  Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

  丙型肝炎病毒抑制剂公开了具有以下通式：其中R1、R2、R3、R'、B、Y和X在描述中有所描述。还公开了包含该化合物的组合物以及使用该化合物抑制HCV的方法。